Interferon-producing killer dendritic cell-based immunotherapy for gastrointestinal cancer

探索在小鼠模型中诱导产生干扰素的杀伤树突状细胞（IKDCs）的有效方法。小鼠脾细胞经CpG、Flt-3配体、IL-15、IL-18培养后，ikdc的数量增加到未刺激时的1.34-6.38倍。然后，使用小鼠低免疫原性结直肠癌MC38模型评估IKDC对已建立肿瘤的治疗效果。当ikdc接种于荷瘤小鼠时，与骨髓树突状细胞处理的小鼠相比，肿瘤的生长明显受到抑制。因此，应考虑以ikdc为基础的免疫治疗在临床应用。

Effective methods for inducing interferon-producing killer dendritic cells (IKDCs) in a mouse model were explored. When murine splenocytes were cultured with CpG, Flt-3 ligand, IL-15, and IL-18, the number of IKDCs was increased to 1.34-6.38 times as much as that in splenocytes without any stimulation. Then, the therapeutic effects of IKDC on the established tumors were assessed using a murine poorly immunogenic colorectal cancer, MC38 model. When IKDCs were inoculated in tumor-bearing mice, the outgrowths of the tumors were significantly suppressed compared with those in mice treated with myeloid dendritic cells. Therefore, IKDC-based immunotherapy should be considered for clinical application.